01 / The founder
Biography
CEO of Rege Nephro, a Kyoto University iPSC spinout developing kidney disease therapies; appointed Representative Director in 2023, not the company's original founder.
02 / Editorial
Why we're watching
Rege Nephro closed a ~$10.6M/¥1.22B round for its ADPKD drug candidate RN-014, but Morinaka is CEO rather than the company's founder (founder is Prof. Kenji Osafune).
03 / The company
Rege Nephro
Biotech · Japan · series-a
04 / Verification
What we verified
Company site lists founder/Chief Scientific Advisor as Prof. Kenji Osafune; Morinaka is CEO/Representative Director, not founder as stated in input — flagged for verification. Founder attribution or company status not independently confirmed; score withheld.
05 / References